Mimedx (MDXG) Cost of Revenue (2011 - 2026)

Mimedx (MDXG) has 16 years of Cost of Revenue data on file, last reported at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 4.89% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $73.8 million (up 15.99% YoY), and the FY2025 full-year result was $73.0 million, up 21.54% from the prior year.
• Cost of Revenue fell to $17.4 million in Q1 2026, from $19.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $19.1 million in Q4 2025 to a low of $9.9 million in Q1 2022.
• A 5-year average of $14.9 million and a median of $14.8 million in 2023 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 102.44% in 2022, while the deepest fall reached 7.34% in 2022.
• Tracing MDXG's Cost of Revenue over 5 years: stood at $14.4 million in 2022, then retreated by 3.67% to $13.8 million in 2023, then increased by 22.16% to $16.9 million in 2024, then advanced by 12.69% to $19.1 million in 2025, then decreased by 8.85% to $17.4 million in 2026.
• Business Quant data shows MDXG's Cost of Revenue at $17.4 million in Q1 2026, $19.1 million in Q4 2025, and $18.7 million in Q3 2025.